Former Chief Financial Officer · Candel Therapeutics, Inc. (CADL)

Jason Amello

FY2023 is the first fiscal year CompBrief holds for Jason Amello as a named executive officer of Candel Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$692,025

Salary $466,045Stock awards $123,203

3rd of 3 named executive officers at Candel Therapeutics by FY2023 total.

3 named officers on file for Candel Therapeutics, FY2023

Jason Amello’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Candel Therapeutics’s whole pay program stands against its peers

  • Candel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CADL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 30, 2024 (DEF 14A).

Free

Get Jason Amello’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jason Amello compensation by year

Candel Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Candel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$466,045
Bonus$0
Stock awards$123,203
Option awards$89,577
Non-equity incentive$0
Pension and deferred compensation$0
All other$13,200
Total$692,025

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed May 30, 2024, accession 0001193125-24-150379, and prior-year filings.

How this page was built: the Candel Therapeutics, Inc. filed document, accession 0001193125-24-150379. Every figure is read from that document and cited to the page and table it appears in. Filed May 30, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU125,717$184,804—
RSU45,438$66,794—
Option158,125—$3.21
Option75,000—$1.29

Per the Outstanding Equity Awards at Fiscal Year-End table in Candel Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Candel Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Paul TakChief Executive Officer$1,484,759
Francesca BaroneChief Scientific Officer$706,876
Jason Amello · this pageFormer Chief Financial Officer$692,025

The full Candel Therapeutics compensation record

free company brief

This page is one person within Candel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Candel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Amello's compensation dossier · One-time report. No refunds.